Methoxyethyl-2-(3-nitrobenzylidene)acetoacetate (intermediate of Cilnidipine)

Superiority:

Shandong Kehui Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical company that strictly complies with GMP requirements and produces high standards. The company was established in May 2017 and is located in the Yellow River Delta Medicine Valley Industrial Park, Gaoqing County, Zibo City. At present, a professional production workshop, strict quality management and inspection system, and a complete EHS management system have been built. The company's main business scope includes the production and sales of APIs and intermediates, pharmaceutical excipients, eye drops, and tablets.

Shandong Kehui Pharmaceutical Co., Ltd. has built three production lines for calcium antagonists, ophthalmic raw materials, and hormones in the first phase. It has technical advantages in the R&D and production of ophthalmic drugs and calcium antagonist antihypertensive drugs, and realizes independent research and development of key technologies. It has the characteristics of small scale and large market, small output and high output value. At present, it can produce 30 tons of calcium antagonist raw materials per year, and 1 tons of ophthalmic raw materials such as bromfenac sodium, nepafenac, pranoprofen, loteprednol, and besifloxacin hydrochloride.

Shandong Kehui Pharmaceutical Co., Ltd. has formed a unique product chain from research, production to sales. The sales are based on the domestic market and face the high-end regulatory market. The products are sold to Europe, the United States, Japan, South Korea, India and other countries.